Search Results

SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia

The goal of our work is to use a “bench to bedside and back” approach to develop new treatments for patients with relapsed/refractory AML. Through gen…

Advances in Treatment for Chronic Lymphocytic Leukemia (CLL)

Topics Covered We invite you to learn more about: Current and emerging therapies for CLL Managing side effects to promote a better quality of lif…

Chronic Myelomonocytic Leukemia (CMML) Clinical Trial Travel Fund

Assists eligible patients diagnosed with Chronic Myelomonocytic Leukemia, being evaluated for or participating in a clinical trial, who are United Sta…

Exploiting Novel Therapeutic Vulnerabilities in Chronic Myelomonocytic Leukemia

The overall objective of this project is to identify novel pathways that may be targeted for therapeutic benefit in CMML. We have identified abnormal …

Making the Rare Seen: Chronic Myelomonocytic Leukemia (CMML)

Highlights In Therapy For Chronic Lymphocytic Leukemia (CLL)

Key Insights: Treating Adult Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia: Patient Experience Not Well Understood

Chronic Myeloid Leukemia: Patient Experience Not Well Understood FOR IMMEDIATE RELEASE Linda House -- [email protected] Andrea Greif --…

What’s on the Horizon for Chronic Lymphocytic Leukemia?

Topics Covered We invite you to learn more about: Diagnosing chronic lymphocytic leukemia (CLL) New and emerging therapies Supportive care and …

The Leukemia & Lymphoma Society Honors Dr. Sherie Morrison

On Wednesday, November , The Leukemia & Lymphoma Society California Southland Chapter held a dinner to honor Dr. Sherie Morrison, a preeminent researc…

What's on the Horizon for Chronic Myeloid Leukemia?

[Click here to enlarge.] Topics Covered We invite you to learn more about: Audio Replay …

LLS PedAL: Precision Medicine for Children with Leukemia

As part of The LLS Children’s Initiative, LLS is working with a team of renowned pediatric oncologists to lay the groundwork for a global precision me…

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, December , – Kura Oncology, Inc. (NASDAQ: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines fo…

Mechanisms of oncogenic transcription in NPM1-mutant myeloid leukemia

NPM1-mutated leukemia is the most common AML in adult and characterized by upregulations of HOXA/B genes and MEIS1. Given the importance of oncogenic …

Functionalizing novel PHIP variants in ancestry-specific acute myeloid leukemia

AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of Black AML pa…

Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)

CMML is a universally lethal blood cancer characterized by increased monocytes (a type of white blood cell) in the peripheral blood and abnormal appea…

Chronic Myeloid Leukemia: Diagnosis, Treatment, and Side Effect Management

Chronic Lymphocytic Leukemia: Diagnosis, Treatment, and Side Effect Management

The Leukemia & Lymphoma Society® is now Blood Cancer United®

Today, The Leukemia & Lymphoma Society—now Blood Cancer United—unveiled its first national advertising campaign in more than a decade.

Histone methyltransferases as key dependencies in SETBP1-mutant leukemias

This study aims to explore how mutant SETBP1 affects histone methyltransferase complexes to drive gene transcription. I will use biochemical, imaging…

The Leukemia & Lymphoma Society's Response to the Israel-Hamas War

The following message was sent to all LLS employees on October , : Dear LLS Community,   As an organization, The Leukemia & Lymphoma Society (LLS) is …

The Leukemia & Lymphoma Society Announces Reimagined Executive Leadership Team

See full multimedia release here.

FDA Expands Use of Leukemia Treatment to Include Children

LLS supported the very first conjugate gemtuzumab ozogamicin, which targets CD33, and was approved in to treat acute myeloid leukemia.

FDA Approves New Targeted Treatment for Acute Myeloid Leukemia

RYE BROOK, N.Y., July , – The U.S. Food and Drug Administration (FDA) last week approved quizartinib (Vanflyta®) in combination with standard chemoth…

Acute Lymphoblastic Leukemia: Diagnosis, Treatment and Side Effect Management

Click Here to ParticipateRecorded on: February , 2025Estimated Time to Complete: . hours2. CE Credits/Contact hours for nurses and social workers avai…